Your browser doesn't support javascript.
loading
SELENBP1 Inhibits the Warburg Effect and Tumor Growth by Reducing the HIF1α Expression in Colorectal Cancer.
Song, Tao; Zhang, Xiaotian; Ren, Jun; Hu, Zhiqing; Wang, Xin; Niu, Gengming.
Afiliación
  • Song T; Department of General Surgery, Shanghai Fifth People's Hospital, Fudan University.
  • Zhang X; Department of General Surgery, Shanghai Fifth People's Hospital, Fudan University.
  • Ren J; Department of General Surgery, Shanghai Fifth People's Hospital, Fudan University.
  • Hu Z; Department of General Surgery, Shanghai Fifth People's Hospital, Fudan University.
  • Wang X; Department of General Surgery, Shanghai Fifth People's Hospital, Fudan University.
  • Niu G; Department of General Surgery, Shanghai Fifth People's Hospital, Fudan University.
Curr Cancer Drug Targets ; 2024 Sep 12.
Article en En | MEDLINE | ID: mdl-39279117
ABSTRACT

INTRODUCTION:

Colorectal cancer (CRC) is experiencing a significant increase in both incidence and mortality rates globally. The expression of Selenium-binding protein 1 (SELENBP1) has been reported to be notably downregulated in various malignancies, yet its biological functions and cellular mechanisms in CRC remain incompletely understood.

METHOD:

In our investigation, we observed the downregulation of SELENBP1 in CRC tissues through quantitative real-time PCR and western blotting and identified a positive correlation between higher SELENBP1 expression and improved survival prognosis using Kaplan-Meier survival analysis. Through loss-of-function and gain-of-function studies, we demonstrated the tumor-suppressive roles of SELENBP1 in CRC, supported by results from both in vitro and in vivo experiments. Furthermore, we uncovered the pivotal functions of SELENBP1 in suppressing aerobic glycolysis in CRC cells by regulating glucose uptake, lactate generation, and extracellular acidification rate.

RESULT:

At a mechanistic level, we found that SELENBP1 inhibits the expression of the key glycolytic modulator hypoxia-inducible factor 1 subunit alpha (HIF1α), and the inhibition of glycolysis by SELENBP1 can be reversed by ectopic expression of HIF1α. Therefore, our study highlights the potential of SELENBP1 as a promising target for CRC therapy, given its significant impact on tumor suppression and reprogrammed glucose metabolism.

CONCLUSION:

These findings contribute to a deeper understanding of the molecular mechanisms underlying CRC progression and may pave the way for the development of targeted therapies for this challenging disease.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Curr Cancer Drug Targets Asunto de la revista: ANTINEOPLASICOS / NEOPLASIAS Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Curr Cancer Drug Targets Asunto de la revista: ANTINEOPLASICOS / NEOPLASIAS Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos